Cellectis S.A.
Business
Cellectis S.A. is a clinical-stage biotechnology company that develops gene-edited cell and gene therapy products using proprietary nuclease and electroporation technologies. It primarily develops allogeneic CAR T-cell product candidates (branded UCART) for immuno-oncology and gene therapy candidates for genetic diseases, alongside technology licensing. Its operations comprise self‑owned research and development pipelines, manufacturing activities (in-house production of clinical and commercial UCART products and raw materials) and collaborative/licensing partnerships with pharmaceutical companies. Cellectis distributes cryopreserved off‑the‑shelf allogeneic cell products for global clinical and potential commercial use, with facilities and trials in Europe and the United States.
Summary from filing dated 2025-03-14
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-67.59M |
| Total assets | $324.72M |
| Total liabilities | $248.82M |
| Stockholders' equity | — |
| Operating cash flow | — |